N/A N=16 Surface Stimulation for Female Sexual Dysfunction
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
Phase 4 N=40 Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Changes in Blood Oxygen Level Dependent (BOLD) Signal Change on Functional MRI — 9.98; 7.67 BOLD signal change
N/A N=45 The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Multiple Sclerosis
Primary: Sexual Dysfunction (as Measured by the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) ) — -0.697 units on a scale
N/A N=25 Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function
Hypertension · Female Sexual Dysfunction
Primary: Change in Female Sexual Function Index — 1.24; 1.42 units on a scale
Phase 4 N=489 Prospective Sexual Function Study for BPH Subjects
Prostatic Hyperplasia
Primary: Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 Months — -0.7; -8.7 Scores on a scale — p=<0.001
Phase 4 N=83 Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning
Healthy
Primary: Change in 17-OH Pregnenolone — 120; 158; 171; 170 ng/dl — p=>0.8
N/A N=15 Effect of Peripheral Neuromodulation on Vaginal Blood Flow - Study 2
Female Sexual Dysfunction · Female Sexual Dysfunction Due to Physical Condition
Primary: Maximum Percent Change in Vaginal Pulse Amplitude (VPA) From the Average Baseline Value — 119.8; 94.3; 135.4; 113.5 percent change of VPA
Phase 3 N=117 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Alopecia
Primary: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period — 5; 9 Participants — p=0.27
Phase 2 N=80 Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men
Sexual Dysfunctions, Psychological · Hypoactive Sexual Desire Disorder · Erectile Dysfunctions
Primary: Number of Participants With a Score of ≤2 (Much/Very Much Improved) on the Clinical Global Impression Scale Adapted for Sexual Function (CGI-SF) at Week 6 Between…
Phase 3 N=217 Effects of SH T00658ID on Libido
Contraception · Libido
Primary: Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS) — 6.45; 5.98 scores on a scale
N/A N=220 Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients
End Stage Renal Disease · Sexual Dysfunction, Physiological · Pain
Primary: Change in Pain, Sexual Dysfunction, and Depression Symptoms — -3.12; -3.7; 0.62; 0.71 units on a scale
N/A N=79 Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction
Female Sexual Dysfunction
Primary: Female Sexual Function Index (FSFI) — 16.72; 16.88; 22.02; 21.22 score on a scale
N/A N=553 Characteristics of Sexual Dysfunction in Patients With Lung Cancer
Lung Cancer · Sexual Dysfunction
Primary: Number of Participants With Different Type, Frequency and Severity of Sexual Dysfunction — 71; 275; 76; 51 Participants
Phase 4 N=176 Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied
Impotence
Primary: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index at the End of the DB Treatment (Week 8) — 80.27; 62.15 scores on a scale — p=<0.0001
Phase 2 N=76 A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
Ejaculatory Dysfunction · Hypogonadism
Primary: Change From Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks — 3.61; 2.95 units…
N/A N=61 A Mindfulness-based Intervention for Older Women With Low Sexual Desire
Hypoactive Sexual Desire Disorder · Sexual Dysfunction · Female Sexual Dysfunction
Primary: Feasibility - Number of Enrolled Women Participating in All Sessions — 15; 22 Participants — p=0.027
Phase 4 N=361 Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers
Healthy Volunteers
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis…
N/A N=47 Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction
Female Sexual Dysfunction · Polycystic Ovary Syndrome
Primary: Sexual Function — 24.8; 26.0 score on a scale — p=0.71
N/A N=178 Sexual Function and Wellbeing in Males With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and After Preoperative Radiotherapy. — 11.3; 11.9; 9.3 nmol/L — p=0.014
N/A N=40 Recovery of Bladder and Sexual Function After Spinal Cord Injury
Spinal Cord Injuries
Primary: Bladder Storage — 278.5; 447.75; 580.5; 313.0 mLH2O
N/A N=20 Penile Nerve Stimulation for Treatment of Delayed Ejaculation
Delayed Ejaculation
Primary: International Index of Erectile Function (IIEF) Scale Score — 7.5; 9.7 score on a scale
Phase 3 N=447 Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
Treatment Outcome
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8 — 8.8; 6.6 scores on a scale — p=0.013
Phase 4 N=50 Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery
Caloric Restriction · Exercise
Primary: Body Composition at the End of Each Study Phase — 78.3; 78.0; 73.3; 75.8 kilograms
Phase 3 N=31 Testosterone Replacement Therapy in Chronic Spinal Cord Injury
Spinal Cord Injury · Hypogonadism
Primary: Dual Energy X-ray Absorptiometry (DXA) Assessment of Lean Tissue Mass (LTM) — 53.1; 50.5 kilograms — p=<0.01
N/A N=142 Sexual Function and Wellbeing in Females With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and 1 Year After Surgery. — 0.6; 0.6; 0.6; 0.5 nmol/l — p=0.004
N/A N=98,832 Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Erectile Dysfunction · Cardiovascular Diseases · Male Urogenital Diseases
Primary: Percentage of Participants With Underlying Condition Until Day -1 of the Index PDE5i Prescription — 70.23; 55.73 Percentage of participants — p=<0.001
N/A N=120 The Impact and Benefit of Physical Activity on Premature Ejaculation
Premature Ejaculation
Primary: Premature Ejaculation Diagnostic Tool (Total Score) — 14.5; 13.7; 13.7; 8.9 scores on a scale
Phase 3 N=16 Safety and Effectiveness Study of Maca Root to Treat Antidepressant-Induced Sexual Dysfunction
Depression · Sexual Dysfunction
Primary: Change in Massachusetts General Hospital Sexual Dysfunction Inventory Scores — .249; .017 score on a scale — p=.016
N/A N=9 Effect of Peripheral Neuromodulation on Vaginal Blood Flow
Female Sexual Dysfunction · Spinal Cord Injuries
Primary: Percent Change in Average Vaginal Pulse Amplitude (VPA) During Stimulation From the Average Baseline Value — 3.3; 3.5 Percent change